Karyopharm Therapeutics Inc.
KPTI
$5.40
$0.459.09%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -0.55% | 1.77% | -0.23% | -5.16% | -7.03% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -0.55% | 1.77% | -0.23% | -5.16% | -7.03% |
| Cost of Revenue | 21.55% | 228.27% | 191.79% | 202.42% | 249.75% |
| Gross Profit | -1.32% | -17.11% | -20.38% | -15.73% | -9.36% |
| SG&A Expenses | -12.47% | -14.64% | -14.72% | -11.94% | -9.30% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -3.95% | -0.20% | 0.70% | -3.52% | -6.74% |
| Operating Income | 7.79% | 2.43% | -1.76% | 1.72% | 6.40% |
| Income Before Tax | 46.51% | 37.50% | 36.56% | 7.44% | 13.43% |
| Income Tax Expenses | -82.35% | 11.28% | -6.35% | 16.04% | -12.47% |
| Earnings from Continuing Operations | 46.60% | 37.41% | 36.50% | 7.39% | 13.43% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 46.60% | 37.41% | 36.50% | 7.39% | 13.43% |
| EBIT | 7.79% | 2.43% | -1.76% | 1.72% | 6.40% |
| EBITDA | 7.68% | 2.26% | -2.03% | 1.42% | 6.37% |
| EPS Basic | 50.03% | 43.33% | 46.11% | 31.73% | 38.32% |
| Normalized Basic EPS | 20.23% | 17.58% | 22.85% | 26.94% | 36.67% |
| EPS Diluted | 22.01% | 16.99% | 22.69% | 31.74% | 38.31% |
| Normalized Diluted EPS | 23.20% | 20.32% | 25.32% | 26.94% | 36.67% |
| Average Basic Shares Outstanding | 6.68% | 10.24% | 17.05% | 26.31% | 39.56% |
| Average Diluted Shares Outstanding | 13.99% | 17.97% | 25.44% | 26.31% | 39.56% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |